This compound represents the first specific IL-23 inhibitor as approved therapy for moderately to severely active forms of CD in adult individuals who experienced an inadequate response to or were not tolerant to conventional or a biologic pharmacotherapy, in the European Union, USA, and Canada in 2022 (Dubinsky M. et al., 2023; European Medicines Agency, 2023a). Here, IL23A is linked to Cowden disease.